SCHEMBL4564168

SCHEMBL4564168

FC(F)(F)Oc1ccc(C2CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
KDM1A O60341 2/20 0.46
RCOR1 Q9UKL0 1/20 0.46
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
EPHX2 P34913 3/20 0.42
FAAH O00519 1/20 0.41
SLC6A4 P31645 1/20 0.41
DHODH Q02127 1/20 0.41
HTR2C P28335 2/20 0.41
MAPT P10636 1/20 0.41
EPHX1 P07099 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
GRM2 Q14416 1/20 0.40
NISCH Q9Y2I1 1/20 0.40
GRIN2B Q13224 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8455758 0.92 MEN1 (0.52) L3MBTL1KDM1ARCOR1MEN1KMT2A
SCHEMBL14229002 0.91 ESR2 (0.52) L3MBTL1KDM1ARCOR1MEN1KMT2A
SCHEMBL8596553 0.91 L3MBTL1 (0.42) L3MBTL1KDM1ARCOR1MEN1KMT2A
SCHEMBL22816583 0.91 ESR2 (0.53) L3MBTL1KDM1ARCOR1MEN1KMT2A
SCHEMBL8596557 0.91 KDM1A (0.44) L3MBTL1KDM1ARCOR1MEN1KMT2A
SCHEMBL14817292 0.91 ESR2 (0.53) L3MBTL1KDM1ARCOR1MEN1KMT2A
SCHEMBL8596551 0.91 L3MBTL1 (0.42) L3MBTL1KDM1ARCOR1MEN1KMT2A
SCHEMBL22816126 0.91 ESR2 (0.53) L3MBTL1KDM1ARCOR1MEN1KMT2A
SCHEMBL7724468 0.90 EPHX2 (0.48) L3MBTL1KDM1ARCOR1MEN1KMT2A
SCHEMBL8767731 0.89 MEN1 (0.44) L3MBTL1KDM1ARCOR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260007684-A1 AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U S INC (US) 2026-01-08 US disclosed
US-20220153729-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-05-19 US disclosed
US-10154995-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-12-18 US disclosed
EP-3089788-B1 SERINE/THREONINE KINASE INHIBITORS GENENTECH INC (US) 2018-10-24 EP disclosed
CN-108430993-A TANK-BINDING KINASE INHIBITOR COMPOUNDS 吉利德科学公司 2018-08-21 CN disclosed
US-20170348310-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2017-12-07 US disclosed
US-9763942-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2017-09-19 US disclosed
EP-3089788-A1 SERINE/THREONINE KINASE INHIBITORS Genentech, Inc. (US) 2016-11-09 EP disclosed
US-20160303126-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 US disclosed
WO-2015103133-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-07-09 WO disclosed
EP-1861359-B1 N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN PFIZER (US) 2012-11-14 EP disclosed
EP-2134692-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION Wyeth a Corporation of the State of Delaware (US) 2009-12-23 EP disclosed
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins WYETH (US) 2008-10-16 US disclosed
WO-2008121817-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION WYETH (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160303126-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, TTBK1, MAP3K11 L3MBTL1 1885/4885KDM1A 3144/4885RCOR1 2253/4885
US-10154995-B2 Serine/threonine kinase inhibitors MAP3K1, TTBK1, MAP3K11 L3MBTL1 1885/4885KDM1A 3144/4885RCOR1 2253/4885
US-20170348310-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, TTBK1, MAP3K11 L3MBTL1 1885/4885KDM1A 3144/4885RCOR1 2253/4885
US-20220153729-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 L3MBTL1 3641/4885KDM1A 4578/4885RCOR1 1678/4885
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins VCAM1, ICAM1, SELE L3MBTL1 4228/4885KDM1A 3482/4885RCOR1 1541/4885
US-20260007684-A1 AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF NOD1, NLRP3, NOD2 L3MBTL1 1893/4885KDM1A 4256/4885RCOR1 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.